FDA Articulates Design Principles For Pivotal Trials In Final Guidance
This article was originally published in The Gray Sheet
Executive Summary
The agency prefers device pivotal trials to be randomized, double-blinded and controlled, but understands that this is “neither feasible nor practical” for some devices, according to a Nov. 7 final guidance.